Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

Launched by C5 BIOMEDICAL · Nov 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well certain human placental membrane products work alongside standard treatment for people with nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The goal is to see if these additional products help improve healing compared to standard care alone over a 12-week period. The trial is currently recruiting participants aged 18 and older who have been diagnosed with type 1 or type 2 diabetes and have an ulcer on their foot that has not shown signs of healing after at least four weeks of standard treatment.

To participate, individuals must have specific types of ulcers and meet other health criteria, such as having enough blood flow to the affected limb. Participants will need to come in for weekly visits during the study and follow certain care guidelines for their ulcers. It's important to note that those with infected ulcers, severe medical conditions, or who are on certain medications may not be eligible for the trial. This study aims to find effective ways to help heal stubborn ulcers, which can be a significant problem for people with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for DFU:
• • 1. At least 18 years of age or older.
• • 2. Must have diagnosis of type 1 or 2 Diabetes mellitus.
• • 3. At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device.
• • 4. Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit.
• • 5. Target ulcer located on the foot with at least 50% of the ulcer below the malleolus.
• • 6. Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.
• 7. Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
• • 1. ABI between 0.7 and \<= 1.3
• • 2. TBI \>= 0.6
• • 3. TCOM \>= 40 mmHg
• • 4. PVR: biphasic
• • 8. If subject has two or more ulcers, they must be separated by 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
• • 9. Target ulcer must be located on the plantar aspect of the foot and must be offloaded for at least 14 days prior to enrollment.
• • 10. Subject must consent to using the prescribed offloading method for the duration of the study.
• • 11. Subject must agree to attend weekly study visits.
• • 12. Subject must be willing and able to participate in the consent process.
• Exclusion Criteria for DFU:
• • 1. Subject is known to have a life expectancy of \< 6 months.
• • 2. Subject's target ulcer is not secondary to diabetes.
• • 3. Target ulcer is infected or there is cellulitis in the surrounding skin.
• • 4. Target ulcer exposes tendon or bone.
• • 5. Evidence of osteomyelitis complicating the target ulcer.
• • 6. Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
• • 7. The subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
• • 8. Subject is taking hydroxyurea.
• • 9. Subject has applied topical steroids to the ulcer surface within one month of initial screening.
• • 10. Subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
• • 11. Subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
• • 12. The surface area of the subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
• • 13. The surface area measurement of the subject's target ulcer decreases by 20% or more during the active 2-week screening phase.
• • 14. Subject has acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
• • 15. Subject is a woman who is pregnant or considering becoming pregnant in the next 6 months.
• • 16. Subject has end stage renal disease requiring dialysis.
• • 17. Subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
• • 18. The subject, in opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.
• • 19. Subject was treated with hyperbaric oxygen therapy or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to screening.
• • 20. Subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment.
• Inclusion Criteria for VLU:
• • Potential subjects are required to meet all the following criteria for enrollment in the study.
• • 1. Subjects must be at least 18 years of age or older.
• • 2. At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20 cm2 measured post-debridement.
• • 3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
• • 4. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks.
• 5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
• • 1. ABI between 0.7 and ≤ 1.3;
• • 2. TBI ≥ 0.6;
• • 3. TCOM ≥ 40 mmHg;
• • 4. PVR: biphasic.
• • 6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
• • 7. The potential subject must agree to attend the weekly study visits required by the protocol.
• • 8. The potential subject must be willing and able to participate in the informed consent process.
• Exclusion Criteria for VLU:
• • 1. The potential subject is known to have a life expectancy of \< 6 months.
• • 2. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.
• • 3. The target ulcer exposes tendon or bone.
• • 4. There is evidence of osteomyelitis complicating the target ulcer.
• • 5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
• • 6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
• • 7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
• • 8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
• • 9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.
• • 10. Women who are pregnant or considering becoming pregnant within the next 6 months.
• • 11. The potential subject has end stage renal disease requiring dialysis.
• • 12. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.
• • 13. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
• • 14. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
• • 15. The subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment.
• • 16. A subject has a wound with active or latent infection is excluded.
• • 17. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.